うつ病治療薬の世界市場：2022-2028年

世界のうつ病治療薬の市場規模は、2020年から2027年の予測期間中に4.1%のCAGRで大きく成長すると予測されています。

世界でうつ病の有病率が上昇しており、同市場の成長を推進しています。また、精神疾患に対する意識の高まりや、うつ病の罹患率が高い老年人口の増加も市場成長を加速させる要因のひとつとなっています。

当レポートでは、世界のうつ病治療薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

• 主要企業分析
• 主要戦略分析

第4章 市場決定要因

• 推進要因
• 抑制要因
• 機会

第5章 市場分析：区分別

• 世界のうつ病治療薬市場：薬剤タイプ別
  • SSRI (選択的セロトニン再取り込み阻害薬)
  • 三環系抗うつ薬
  • SNRI (セロトニンノルアドレナリン再取り込み阻害薬)
  • モノアミン酸化酵素阻害薬
  • その他

第6章 地域分析

• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 企業プロファイル

• Alkermes Plc
• Allergen Plc
• AstraZeneca plc
• Bausch Health Companies, Inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche AG
• Garmin Ltd.
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Lief Therapeutics
• Lupin Ltd.
• MagVenture, Inc.
• Mylan N.V.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

• 1. GLOBAL DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE, 2019-2027 ($ MILLION)
• 2. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUGS REGION, 2019-2027 ($ MILLION)
• 3. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
• 4. GLOBAL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
• 5. GLOBAL MONOAMINE OXIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
• 6. GLOBAL OTHER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
• 7. GLOBAL DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2027 ($ MILLION)
• 8. NORTH AMERICAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2027 ($ MILLION)
• 9. NORTH AMERICAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2027 ($ MILLION)
• 10. EUROPEAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2027 ($ MILLION)
• 11. EUROPEAN DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2019-2027 ($ MILLION)
• 12. ASIA-PACIFIC DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2027 ($ MILLION)
• 13. ASIA-PACIFIC DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2019-2027 ($ MILLION)
• 14. REST OF THE WORLD DEPRESSION TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2019-2027 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL DEPRESSION TREATMENT MARKET SIZE, 2-19-2027 ($ MILLION)
• 2. GLOBAL DEPRESSION TREATMENT MARKET SHARE BY DRUG TYPE, 2019 VS 2027 (%)
• 3. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
• 4. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
• 5. GLOBAL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
• 6. GLOBAL MONOAMINE OXIDASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
• 7. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2019 VS 2027 (%)
• 8. GLOBAL DEPRESSION TREATMENT RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019 VS 2027 (%)
• 9. US DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 10. CANADA DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 11. UK DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 12. FRANCE DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 13. GERMANY DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 14. ITALY DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 15. SPAIN DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 16. REST OF EUROPE DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 17. INDIA DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 18. CHINA DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 19. JAPAN DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 20. REST OF ASIA-PACIFIC DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)
• 21. REST OF THE WORLD DEPRESSION TREATMENT MARKET SIZE, 2019-2027 ($ MILLION)

Choose License Type

Single user $4500, $3375 Multi user $6000, $4500

100% Secured Payment

SHARE ON:

Benefits Of Buying From Us

Covers more than 15 major industries, which are further segmented into 90+ sectors

65% of our clients are loyal customers

120+ countries are covered in analysis

currently servicing 1000+ customers globally

100+ paid data sources mined to research

Our expert team will assist you with all research need and customization

Our expert research analyst will resolve your every query before and after purchasing the report

Related Reports

Infertility Diagnosis and Treatment Market

Male Infertility Diagnosis and Treatment Market

Aneurysm Diagnostic And Treatment Market

Cyclin Dependent Kinase (CDK) Inhibitors Market

Vitamin B Market

Antiepileptic Drugs Market

Global Depression Treatment Market Size, Share & Trends Analysis Report by Drug Type (Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, and Others) Forecast Period 2020-2027

The global depression treatment market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period of 2020-2027. Depression treatments are the type of prescription given to alleviate the symptoms of anxiety disorders, mild chronic depression, and Major Depressive Disorder (MDD). The rising prevalence of depression among the global population is the major factor driving the growth of the depression treatment market.

Besides, the increasing awareness about mental illness, and the growing geriatric population with a higher rate of depression, is another factor accelerating the market growth. According to the report of the World Health Organization (WHO) published in January 2020, there are around 800,000 suicide-related mortalities every year, and 264 million people of all ages suffer from depression globally.

Moreover, depression is the second leading cause of suicide in the young generation which is expected to increase due to change in lifestyle and increasing workload. The presence of depression disorder cases is higher in the US. According to the estimates of Anxiety and Depression Foundation facts and statistics, 6.8 million adults, or 3.1% of the US population have been affected by a generalized anxiety disorder. In line with this, 6 million adults, or 2.7% of the US population are affected by panic disorder. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues may further lead to depression, which in turn, creates demand for depression treatment drugs.

Segmental Outlook

The global depression treatment market is segmented on the basis of drug type into selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and others.

Selective Serotonin Reuptake Inhibitors (SSRIs) in Drug Type Segment Hold Significant Share

The Selective Serotonin reuptake inhibitors (SSRI) segment is anticipated to grow at a significant pace during the forecast period. The SSRI is a type of drug used to treat mental illnesses such as depression and anxiety disorder by elevating the extracellular levels of serotonin. Selective serotonin reuptake inhibitors are widely used across the globe as they are highly effective in the treatment of depression. These are the most commonly prescribed antidepressant drugs, as it possesses maximum benefits with fewer side effects as compared to other drugs. Similar to other antidepressants, certain SSRIs are prescribed as a treatment for chronic pain conditions.

Regional Outlook

The global depression treatment market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to be the leading region in the global depression treatment market and is expected to remain dominant during the forecast period. The factors contributing to the growth of this region include the presence of a large number of depression cases and the accessibility of antidepressants across the region. In addition, the government policies regarding drug launches and generic drug production are the major factors driving the growth of the depression treatment market. The Asia-Pacific is estimated to be the fastest-growing region in the depression treatment market during the forecast period (2021-2027).

Global Depression Treatment Market Growth, by Region 2021-2027

Global Depression Treatment Market Growth, by Region

Asia-Pacific is projected to have considerable growth in the global depression treatment market.

Asia-Pacific is projected to be the fastest-growing market during the forecast period. The factor contributing to the growth of the depression treatment market in this region includes the rising prevalence of psychiatric disorders. Besides, the development of new therapies and devices to reduce the depression rate by investing high amounts through key market players are the key factors for the market growth. Moreover, the production of new antidepressant drugs in emerging countries such as China, India, Japan, and others is anticipated to drive the depression treatment market in the region.

Market Players Outlook

Some of the key players of the depression market include Eli Lilly and Co., Johnson & Johnson, Pfizer, Inc., Merck & Co., Inc., H. Lundbeck A/S., F. Hoffmann-La Roche Ltd, and others. In order to gain a strong position in the market, these players adopt various marketing strategies such as mergers & acquisitions, R&D, product launch, and geographical expansion so on. For instance, in August 2019, Lupin, a pharmaceutical company had launched an antidepressant drug Fluoxetine Tablets USP, 10 mg and 20 mg. The company had received the US FDA approval for Prozac which is indicated for the treatment of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder.

The Report Covers

Market value data analysis of 2019 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global depression treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion
• 2.3. Regulations

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
  • 3.1.4. Recent Developments
• 3.2. Key Strategy Analysis

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Depression Treatment Market by Drugs Type
  • 5.1.1. Selective Serotonin Reuptake Inhibitors
  • 5.1.2. Tricyclic Antidepressants
  • 5.1.3. Serotonin-Norepinephrine Reuptake Inhibitors
  • 5.1.4. Monoamine Oxidase Inhibitors
  • 5.1.5. Others

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Alkermes Plc
• 7.2. Allergen Plc
• 7.3. AstraZeneca plc
• 7.4. Bausch Health Companies, Inc.
• 7.5. Eli Lilly and Co.
• 7.6. F. Hoffmann-La Roche AG
• 7.7. Garmin Ltd.
• 7.8. GlaxoSmithKline plc
• 7.9. H. Lundbeck A/S
• 7.10. Johnson & Johnson Services, Inc.
• 7.11. Lief Therapeutics
• 7.12. Lupin Ltd.
• 7.13. MagVenture, Inc.
• 7.14. Mylan N.V.
• 7.15. Novartis AG
• 7.16. Otsuka Pharmaceutical Co., Ltd.
• 7.17. Pfizer, Inc.
• 7.18. Sanofi SA
• 7.19. Takeda Pharmaceutical Co. Ltd.
• 7.20. Teva Pharmaceutical Industries Ltd.